Motohara K, Endo F, Matsuda I, Iwamasa T
J Pediatr Gastroenterol Nutr. 1987 Jan-Feb;6(1):42-5. doi: 10.1097/00005176-198701000-00008.
We evaluated plasma PIVKA-II (protein induced by vitamin K absence or antagonist-II, acarboxy prothrombin) levels in three infants with hepatoblastoma as a tumor marker. PIVKA-II levels were highly elevated in all three patients. Vitamin K administration, performed in two patients, resulted in only moderate reduction of PIVKA-II levels. Chemotherapy against tumor cells reduced the PIVKA-II levels without exception. Immunohistochemical study of the liver tissue indicated the presence of PIVKA-II in the hepatoblastoma cell. These findings suggest that elevated PIVKA-II in these patients was not due to nutritional vitamin K deficiency, but to excess production of tumor cells. A measurement of plasma PIVKA-II may be useful as a new marker of hepatoblastoma.
我们评估了3例肝母细胞瘤患儿的血浆异常凝血酶原（维生素K缺乏或拮抗剂-II诱导蛋白，脱羧基凝血酶原）水平作为肿瘤标志物。3例患者的异常凝血酶原水平均显著升高。2例患者接受了维生素K治疗，结果异常凝血酶原水平仅适度降低。针对肿瘤细胞的化疗无一例外地降低了异常凝血酶原水平。肝组织的免疫组化研究表明肝母细胞瘤细胞中存在异常凝血酶原。这些发现提示，这些患者异常凝血酶原升高并非由于营养性维生素K缺乏，而是肿瘤细胞过度产生所致。检测血浆异常凝血酶原可能作为肝母细胞瘤的一种新标志物。
